Neuroone Medical Technologies (NMTC) Gains from Investment Securities (2024 - 2026)

Neuroone Medical Technologies (NMTC) has reported Gains from Investment Securities for 3 consecutive years, with -$405702.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gains from Investment Securities fell 26.93% year-over-year to -$405702.0; the trailing twelve-month figure through Jun 2026 stood at -$305420.0 (changed N/A YoY), and the FY2025 full-year result was -$784670.0, down 339.89% from the prior year.
• Gains from Investment Securities declined to -$405702.0 in Q2 2026 per NMTC's latest filing, from $8271.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $314751.0 in Q3 2025 and bottomed at -$405702.0 in Q2 2026.
• Historically, Gains from Investment Securities has averaged -$200691.6 across 3 years, with a median of -$319625.0 in 2025.
• The widest YoY moves for Gains from Investment Securities: up 102.12% in 2026, down 26.93% in 2026.
• Over 3 years, Gains from Investment Securities stood at -$389445.0 in 2024, then surged by 42.81% to -$222740.0 in 2025, then sank by 82.14% to -$405702.0 in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$405702.0, $8271.0, and -$222740.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.